Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159708 | 0.87 | OPRK1 (0.59) | ALDH1A1TRPM8TRPV1OPRM1OPRD1 | |
| SCHEMBL4081568 | 0.85 | HTT (0.55) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL9329761 | 0.82 | HTT (0.53) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL19326604 | 0.82 | HTT (0.53) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL6419591 | 0.81 | ALDH1A1 (0.50) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL11795941 | 0.80 | HDAC3 (0.56) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL4974601 | 0.80 | HDAC3 (0.61) | HDAC3HDAC1HDAC2HDAC8NCOR2 | |
| SCHEMBL134524 | 0.79 | TSHR (0.60) | ALDH1A1TSHRCNR2CA2OPRM1 | |
| SCHEMBL231061 | 0.78 | OPRK1 (0.63) | ALDH1A1TSHRTRPM8TRPV1OPRM1 | |
| SCHEMBL11673147 | 0.78 | HDAC3 (0.62) | HDAC3HDAC1HDAC2HDAC8NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016065602-A1 | INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065582-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-19 | — | — | US | disclosed |
| EP-1807436-B1 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2359862-B1 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8426477-B1 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| EP-1848460-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | Intezyne Technologies Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1833958-A2 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | Intezyne Technologies Incorporated (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1807436-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | Intezyne Technologies Incorporated (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. | 2006-10-26 | — | — | US | disclosed |
| WO-2006107903-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006086325-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060172914-A1 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006074202-A2 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006047419-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | GNE, ALG1, EPHX2 | HDAC3 3213/4885HDAC1 3638/4885HDAC2 4001/4885 |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | HDAC3 1610/4885HDAC1 3189/4885HDAC2 4444/4885 |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | ABCB1, TERT, ABCB4 | HDAC3 3643/4885HDAC1 3664/4885HDAC2 4771/4885 |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | IAPP, APP, TTR | HDAC3 4763/4885HDAC1 4816/4885HDAC2 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.